| 2023-FORT-70255 | |
| Researchers at Purdue University have developed a novel class of small molecules which inhibit the formation of feline and human islet amyloid polypeptide (IAPP). Type 2 diabetes is a disease in which approximately 70% of cases involve the accumulation of IAPP. Pancreatic aggregates of IAPP are also reported in 70% of feline and human patients. Currently, there is no cure for type 2 diabetes in humans and felines and no treatment for pancreatic IAPP aggregates. Purdue researchers discovered three compounds with high efficacy and affinity to both feline and human IAPP. The small molecules reduced aggregation of IAPP at 100 micromolar after 1 hour. These molecules can be utilized as a future therapeutic and to better understand the role of IAPP in feline and human type 2 diabetes. Technology Validation: The potency of these molecules was validated in vitro by fluorescence assays, dynamic light scattering, and electron microscopy. These methods demonstrated the efficacy, selectivity, and ability to inhibit aggregation of IAPP by these small molecules. Advantages: -Inhibits IAPP aggregation -Bioavailable potential -Selective -Moderate to high yield Applications: -Type 2 diabetes -Protein aggregation inhibition -Combinational therapy -Proteopathies |
|
|
|
|
May 2, 2023
Provisional-Gov. Funding
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
